Synergy Pharmaceuticals to Present at the UBS Global Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the UBS Global Healthcare Conference on Wednesday May 20th at 12:00pm (EDT) at the Sheraton New York Times Square Hotel in New York City.

A live webcast of the presentation will be accessible through the Investor Relations section of the company’s website at www.synergypharma.com. A replay of the webcast will be available on Synergy’s website for 60 days.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of gastrointestinal (GI) diseases and disorders. Synergy’s proprietary platform technology is based on the naturally occurring human GI peptide, uroguanylin, a key regulator of normal GI physiology. The company’s first uroguanylin analogue, plecanatide, is in pivotal phase 3 clinical trials for chronic idiopathic constipation and irritable bowel syndrome with constipation. Synergy’s next-generation uroguanylin analogue, SP-333, has successfully completed a phase 2 study for opioid-induced constipation and is currently being explored for ulcerative colitis. For more information, please visit www.synergypharma.com.